Viewing nowCombinationOlmexpos Tablets 5/40 mg (Amlodipine Besylate, Olmesartan Medoxomil)
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation

MFDS item code 201404592 · Approved 2014.10.06 · Insurance code 644913850
Treatment of essential hypertension not controlled with monotherapy
This medication is used when blood pressure is not well controlled with monotherapy of amlodipine or olmesartan medoxomil. It helps lower blood pressure to treat essential hypertension and is effective in reducing the risk of cardiovascular complications. It is used to maintain the health of hypertensive patients and improve blood pressure management.
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) ∘Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
∘Pediatric patients: The safety and efficacy have not been established in pediatric patients under 18 years of age.
This drug can cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used if there is an allergy to any of the ingredients, if pregnant or nursing, or in patients with severe liver impairment, those undergoing renal dialysis, or those with severe aortic stenosis. When starting this medication in a state of dehydration or electrolyte deficiency, hypotension may occur, so treatment should be started with careful monitoring. Since vascular dilation can lead to a rapid drop in blood pressure, caution is required in patients with severe aortic stenosis. Patients with heart problems, particularly those with heart failure or obstructive coronary artery disease, should use this medication cautiously, with continuous monitoring of their condition during treatment. Patients with renal impairment may experience further worsening of renal function when taking this medication. Patients with impaired liver function should also be cautious when taking this drug and may require dose adjustments. During treatment, side effects such as dizziness, headache, hypotension, orthostatic hypotension, fatigue, swelling, nausea, constipation, rash, etc. may occur; if symptoms are severe, consult a healthcare professional. Particularly, potassium levels in the blood may increase, so those taking potassium supplements or potassium-sparing diuretics should have potassium concentration monitored regularly. This drug may interact with other antihypertensive medications or specific drugs; therefore, if taking other medications, it is crucial to inform the doctor or pharmacist. Women who are pregnant or planning to become pregnant should be switched to other antihypertensive agents whose safety has been established, and the use of this drug should be discontinued as soon as pregnancy is confirmed. Since this drug may pass into breast milk and cause side effects in infants, nursing mothers should either discontinue breastfeeding or stop taking this medication. This medication is not recommended for children under 18 years of age as its safety and efficacy in this population have not been established. Older patients may have reduced renal and liver function, thus treatment should start at a lower dose with careful dose adjustments. In cases of overdose, symptoms such as hypotension and tachycardia may occur, necessitating immediate treatment in a medical facility while continuously monitoring blood pressure and heart function. This medication should be stored in a tightly closed container to prevent air and moisture from entering and should be kept at a cool room temperature between 1 and 30 degrees Celsius. It is important to avoid direct sunlight and not to place it in excessively hot or cold places.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to prevent air or moisture from entering and kept at a cool room temperature between 1 and 30 degrees Celsius. It is crucial to avoid direct sunlight and not to expose it to extreme heat or cold.
Pale yellow round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Hyuntex Pharmaceutical Co., Ltd.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilseong IS Co., Ltd.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Unimed Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.